Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Can AbbVie Beat Pfizer in the Atopic Dermatitis Market?

TheMotleyFool

0 0

Can AbbVie Beat Pfizer in the Atopic Dermatitis Market?

Both AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE) recently picked up regulatory approvals for JAK inhibitors for treating atopic dermatitis. In this Motley Fool Live video recorded on Jan. 19, Motley Fool contributors Keith Speights and Brian Orelli discuss whether AbbVie is likely to beat Pfizer in this large market.

Source Fool.com

Like: 0

ABBV

Share